Privat: News - emergers.se

PROLIGHT: Commercial prototype marks an important milestone towards upcoming studies

2024-12-03• Analys, Research

The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) system marks an important development...

Read More →

2024-11-28• Analys, Research

Prolight continues to make progress with its proprietary Psyros platform, with a pre-validation study, including fresh blood samples from...

Read More →

2024-11-08• Analys, Research

NEX-22 is progressing as expected, with the last patient in Phase I treated, results anticipated later in November, and Phase IIb scheduled...

Read More →

2024-11-01• Analys, Research

On Friday Nov 1st, 2024 Crunchfish hosted a webinar in connection with the Q3’24 report, where CEO Joachim Samulesson was interviewed...

Read More →

RESEARCH COLLABORATION WITH ENLIGHT RESEARCH Q3 Sales and Profits beat estimates, but the economic downturn affects demand. In 2025, we...

Read More →

2024-09-23• Analys, Research

As discussed in our previous update, Crunchfish has now settled on a path forward for the company’s financing. On Friday after the...

Read More →

2024-09-09• Analys, Research

With the dust settling after the acquisition of Sydvaranger and the updated DFS for Dannemora in Q2’24, the next steps for GRANGEX are...

Read More →

2024-08-30• Analys, Research

MODI reported Q2’24 sales largely in line with last year, at SEK 7.4m compared to SEK 7.6m in Q2’23. The gross margin increased by 6ppt...

Read More →

2024-08-29• Analys, Research

Supported by the latest troponin data generated from whole blood samples on the final commercial cartridge design, Prolight is now ready to...

Read More →

2024-08-28• Analys, Research

After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of the GLP-1 analog liraglutide, NEX-22...

Read More →